EFTA-Thailand FTA: Access to medicines and TRIPS



Dr. Jiraporn Limpananont

- Social Pharmacy Research Unit (SPRU)

 Faculty of Pharm. Sciences,

 CHULALONGKORN UNIVERSITY
- FTA Watch
 Coalition of Thai NGO working on FTA

Overview Presentation

- HIV Situation & ARVs Demand
- IPRs Protection in Thailand
- IPRs Protection & Access to Medicines
- EFTA-Thailand FTA & Access to Medicines
- FTA & Right to Health




HIV Situation & ARVs Demand

- untill 2005, HIV infected 1,070,000 adults
- □ 510,000 died
- 560,000 HIV+ and AIDS
- in 2006 new infections 17,000
- □ 37,000 HIV+ and AIDS
- The government policy is to provide the ARVs for the fiscal year 2005 is 80,000 cases
- GPO-vir as the first line ARVs




Estimated number of HIV+ people on ARVs treatment upto 2025








Estimated number of people need first and second line ARVs



NATIONAL DRUG PATENT SYSTEM



IPRs Protection in Thailand



- Drug Patent Situation in Thailand
- Impact in Access to Medicines in Thailand



Drug Patent Situation in Thailand

7

RESULTS:

- 98% PATENTEES WERE FOREIGNERS
- Patent Granting Process Took 7-8 years
 - Filing date to Publishing date 1-1.5 Yrs
 - Publishing date to Exam date
 4-5
 Yrs
 - Exam date to Patent issued date 1.5-2 Yrs
- The number of new drugs still on-patent up to July 2003 was 215 drugs out of 966 drugs (22.4%) and the remaining patent life were 7.5 to 18.2 years.



DAILY COST of ARVS THERAPY

REGIMEN	2001	2002	2003	2004			
	B/G	B/G	B/G	B/G	B(B)	G(B)	
GPO-VIR30 d4T+3TC+NVP AZT+3TC+NVP d4T+3TC+EFV AZT+3TC+EFV AZT+3TC+RTV+IDV d4T+3TC+RTV+IDV d4T+ddI+NVP AZT+3TC+IDV AZT+ddI+RTV+IDV	2.98 2.67 2.30 2.12 1.92 2.05 2.93 1.73 1.77 1.50	10.90 7.65 5.65 3.86 3.19 2.64 2.92 4.06 2.99 1.94 1.77	10.95 7.68 5.99 3.57 3.21 2.79 3.03 4.08 3.60 2.02 1.77	10.95 7.68 5.99 3.57 3.21 2.79 3.03 4.08 3.60 2.02 1.77	438 438 443 495 498 535 530 347 252 444 791	40 57 74 138 155 192 175 85 70 220 448	


TRIPs Plus of EFTA-Thailand FTAs

- Extension of Patent Term
- Data Exclusivity



Patent Granting Process


- Filing date to Publishing date
- Publishing date to Exam date
- Exam date to Patent issued date 1.5-2 Yrs Total
- 1-1.5 Yrs
- 4-5 Yrs
 - - 7-8 Yrs



Extension of patent term

Unreasonable request:

** to compensate for up-front administrative or regulatory delays in granting the original patent






2. Data Exclusivity

Test Data Protection	VN	JD	S G	Chi li	Mo roc co	Au	CA FT A	B R
-TRIPs std -Data Exclusivity -"reasonable period" - 5 yrs -Plus 3 yrs Data Exclusivity by new clinical info.	X	X	X	X	X	XX	XX	XX

In this period no any flexibility in TRIPs can be applied



DATA EXCLUSIVITY & PATENT





Thai Trade Secret Act 2002

Art. 15: As a condition in law requiring of the marketing of pharmaceutical or of agricultural chemical products which utilize new chemical entities, the submission of undisclosed test or other data, to the government agency, the origination of which involves a considerable effort and they are declared to be protected, the government agency must protect such data from disclosure and against unfair commercial use.



TRIPS Article 39.3

- As a condition of approving the marketing of
 - pharmaceutical or agri. chemical products
 - rew chemical entities
 - undisclosed test or other data
- protect such data against
 - disclosure
 - unfair commercial use



unfair commercial use



POST-MARKET SURVEILLANCE

ORIGINALS
-SUBMIT UNDISCLOSED
(SAFETY & EFFICACY DATA)

GENERICS
-SUBMIT BIOEQUIVALENT
STUDY



Conclusion



- High drug price > Inaccessibility to drug
- Obstacle to Thai Drug Industry to develope

Data Protection

Thai drug registration process comply to TRIPs

Extension of Patent Term

Propose for the Technological Co-operation System instead of extension of patent term



